Breast Cancer Research and Treatment

, Volume 97, Issue 1, pp 91–96 | Cite as

Detection of cytokeratin-positive cells in the bone marrow of breast cancer patients undergoing adjuvant therapy

  • Sven Becker
  • Graziella Becker-Pergola
  • Diethelm Wallwiener
  • Erich-Franz Solomayer
  • Tanja Fehm


The presence of cytokeratin-positive cells in the bone marrow of breast cancer patients has been proven to be an independent prognostic factor. Their fate in primary breast cancer patients undergoing adjuvant therapy is of particular interest. We investigated the bone marrow status of 112 patients undergoing postoperative adjuvant treatment before and after therapy. A total of 373 patients with histologically confirmed primary breast cancer underwent bone marrow aspiration at the time of primary surgery. All patients were informed of their bone marrow status and offered repeat aspiration after 12 months. All patients were then treated with adjuvant chemotherapy, endocrine therapy or both based on current treatment recommendations. About 112 patients returned for a second bone marrow aspiration after a mean interval of 12 months following the initiation of adjuvant treatment. In 93 of 112 patients (83%) disseminated tumor cells had been found in the bone marrow before initiation of systemic chemo/endocrine therapy. At the time of follow-up sampling, after surgery and completion of adjuvant chemotherapy, the positivity rate dropped to 24%. Positive bone marrow status during follow-up was only associated with grading (p=0.020). Adjuvant treatment regimens are not able to completely eliminate cytokeratin-positive cells from the bone marrow. Prospective studies need to evaluate, whether these cells could become targets for additional adjuvant therapy.


adjuvant therapy bone marrow breast cancer disseminated tumor cells micrometastasis 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Wiedswang G, Borgen E, Karesen R, Kvalheim G, Nesland JM, Qvist H, Schlichting E, Sauer T, Janbu J, Harbitz T, Naume B. (2003) Detection of isolated tumor cells in bone marrow is an independent prognostic factor in breast cancerJ Clin Oncol 21:3469–3478CrossRefPubMedGoogle Scholar
  2. 2.
    Solomayer EF, Diel IJ, Salanti G, Hahn M, Gollan C, Schutz F, Bastert G. (2001) Time independence of the prognostic impact of tumor cell detection in the bone marrow of primary breast cancer patientsClin Cancer Res 7:4102–4108PubMedGoogle Scholar
  3. 3.
    Mansi JL, Gogas H, Bliss JM, Gazet JC, Berger U, Coombes RC. (1999) Outcome of primary breast cancer patients with micrometastases: a long-term follow-up studyLancet 354:197–202CrossRefPubMedGoogle Scholar
  4. 4.
    Diel IJ, Kaufmann M, Costa SD, Holle R, von Minckwitz G, Solomayer EF, Kaul S, Bastert G. (1996) Micrometastatic breast cancer cells in bone marrow at primary surgery – prognostic value in comparison with nodal statusJ Natl Cancer Inst 88:1652–1658CrossRefPubMedGoogle Scholar
  5. 5.
    French Adjuvant Study Group 2001 Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial. J Clin Oncol 19:602–611Google Scholar
  6. 6.
    Becker S, Becker-Pergola G, Fehm T, Wallwiener D, Solomayer EF, (2005) Her2-expression on disseminated tumor cells from bone marrow – correlation with the primary tumorAnticancer Res 25:2171–2175PubMedGoogle Scholar
  7. 7.
    Fehm T, Sagalowsky A, Clifford E, Beitsch P, Saboorian H, Euhus D, Meng S, Morrison L, Tucker T, Lane N, Ghadimi BM, Heselmeyer-Haddad K, Ried T, Rao C, Uhr J. (2002) Cytogenetic evidence that circulating epithelial cells in patients with carcinoma are malignantClin Cancer Res 8:2073–2084PubMedGoogle Scholar
  8. 8.
    Braun S, Vogl FD, Naume B, Janni W, Osborne MP, Coombes RC, Schlimok G, Diel, IJ, Gerber B, Gebauer G, Pierga JY, Marth C, Oruzio D, Wiedswang G, Solomayer EF, Kundt G, Strobl B, Fehm T, Wong GY, Bliss J, Vincent-Salomon A, Pantel K (2005) A pooled analysis of bone marrow micrometastasis in breast cancerN Engl J Med 353(8):793–802CrossRefPubMedGoogle Scholar
  9. 9.
    Jamshidi K, Swaim WR (1971) Bone marrow biopsy with unaltered architecture: a new biopsy deviceJ Lab Clin Med 77: 335–342PubMedGoogle Scholar
  10. 10.
    Kahlert S, von Koch F, Ditsch N, Untch M. (2004) Adjuvant treatment of breast cancer in 2004. A review of the 8th consensus conference of St. Gallen and new study results. Gynakol Geburtsh Rundsch 44:102–112CrossRefGoogle Scholar
  11. 11.
    Becker S, Becker-Pergola G, Fehm T, Emig R, Wallwiener D, Solomayer EF. (2005) Image analysis systems for the detection of disseminated breast cancer cells on bone marrow cytospinsJ Clin Lab Anal 19:115–119CrossRefPubMedGoogle Scholar
  12. 12.
    Borgen E, Naume B, Nesland JM, Kvalheim G, Beiske K, Fodstad O, et al. (1999) Standardization of the immunological detection of cancer cells in bone marrow and blood: Establishment of objective criteria for the evaluation of immunostained cellsCytotherapy 5:377–388CrossRefGoogle Scholar
  13. 13.
    American Cancer Society. (2004) Cancer Facts & Figures American Cancer Society, Inc., AtlantaGoogle Scholar
  14. 14.
    Veronesi U, Cascinelli N, Mariani L, Greco M, Saccozzi R, Luini A, Aguilar M, Marubini E. (2002) Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancerN Engl J Med 347:1227–1232CrossRefPubMedGoogle Scholar
  15. 15.
    Veronesi U, Banfi A, Saccozzi R, et al. (1977) Conservative treatment of breast cancer: a trial in progress at the Cancer Institute in MilanCancer 39:2822–2826CrossRefPubMedGoogle Scholar
  16. 16.
    Bonadonna G, Brusamolino E, Valagussa P Rossi A, Brugnatelli L, Brambilla C, et al. (1976) Combination chemotherapy as an adjuvant treatment in operable breast cancerN Engl J Med 294:405–410PubMedGoogle Scholar
  17. 17.
    Early Breast Cancer Trialists’ Collaborative Group. (1995) Effects of radiotherapy and surgery in early breast cancer: an overview of the randomized trialsN Engl J Med 333:1444–1455CrossRefGoogle Scholar
  18. 18.
    van Dongen JA, Voogd AC, Fentiman IS, Legrand C, Sylvester RJ, Tong D, van der Schueren E, Helle PA, van Zijl K, Bartelink H. (2000) Long-term results of a randomized trial comparing breast-conserving therapy with mastectomy: European Organization for Research and Treatment of Cancer 10801 trialJ Natl Cancer Inst 92:1143–1150CrossRefPubMedGoogle Scholar
  19. 19.
    Fisher B, Jeong J-H, Anderson S, Bryant J, Fisher ER, Wolmark N. (2002) Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiationN Engl J Med 347:567–575CrossRefPubMedGoogle Scholar
  20. 20.
    Klein CA, Schmidt-Kittler O, Schardt JA, Pantel K, Speicher MR, Riethmuller G. (1999) Comparative genomic hybridization, loss of heterozygosity, and DNA sequence analysis of single cellsProc Natl Acad Sci 96:4494–4499CrossRefPubMedGoogle Scholar
  21. 21.
    Landys K, Persson S, Kovarik J, Hultborn R, Holmberg E. (1998) Prognostic value of bone marrow biopsy in operable breast cancer patients at the time of initial diagnosis: Results of a 20-year median follow-upBreast Cancer Res Treat 49:27–33CrossRefPubMedGoogle Scholar
  22. 22.
    Braun S, Pantel K, Muller P, Janni W, Hepp F, Kentenich CR, Gastroph S, Wischnik A, Dimpfl T, Kindermann G, Riethmuller G, Schlimok G. (2000) Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancerN Engl J Med. 342:525–33 Erratum in: N Engl J Med 343:308 2000CrossRefPubMedGoogle Scholar
  23. 23.
    Gerber B, Krause A, Muller H, Richter D, Reimer T, Makovitzky J, Herrnring C, Jeschke U, Kundt G, Friese K. (2001) Simultaneous immunohistochemical detection of tumor cells in lymph nodes and bone marrow aspirates in breast cancer and its correlation with other prognostic factorsJ Clin Oncol 19:960–971PubMedGoogle Scholar
  24. 24.
    Braun S, Cevatli BS, Assemi C, Janni W, Kentenich CR, Schindlbeck C, Rjosk D, Hepp F. (2001) Comparative analysis of micrometastasis to the bone marrow and lymph nodes of node-negative breast cancer patients receiving no adjuvant therapyJ Clin Oncol 19:1468–1475PubMedGoogle Scholar
  25. 25.
    Braun S, Kentenich C, Janni W, Hepp F, de Waal J, Willgeroth F, Sommer H, Pantel K. (2000) Lack of effect of adjuvant chemotherapy on the elimination of single dormant tumor cells in bone marrow of high-risk breast cancer patientsJ Clin Oncol 18:80–86PubMedGoogle Scholar
  26. 26.
    Schlimok G, Pantel K, Loibner H, Fackler-Schwalbe I, Riethmuller G. (1995) Reduction of metastatic carcinoma cells in bone marrow by intravenously administered monoclonal antibody: towards a novel surrogate test to monitor adjuvant therapies of solid tumoursEur J Cancer 31A:1799–1803CrossRefPubMedGoogle Scholar
  27. 27.
    Hohaus S: Persistence of isolated tumor cells in patients with breast cancer after sequential high dose therapy with peripheral blood stem cell transplantation. Blood 88, 128A (Abstract 501)Google Scholar
  28. 28.
    Janni W, Hepp F, Rjosk D, Kentenich C, Strobl B, Schindlbeck C, Hantschmann P, Sommer H, Pantel K, Braun S. (2001) The fate and prognostic value of occult metastatic cells in the bone marrow of patients with breast carcinoma between primary treatment and recurrenceCancer 92:46–53CrossRefPubMedGoogle Scholar
  29. 29.
    Wiedswang G, Borgen E, Karesen R, Qvist H, Janbu J, Kvalheim G, Nesland JM, Naume B. (2004) Isolated tumor cells in bone marrow three years after diagnosis in disease-free breast cancer patients predict unfavorable clinical outcomeClin Cancer Res 10:5342–5348CrossRefPubMedGoogle Scholar
  30. 30.
    Slade MJ, Singh A, Smith BM, Tripuraneni G, Hall E, Peckitt C, Fox S, Graham H, Luchtenborg M, Sinnett HD, Cross NC, Coombes RC. (2004) Persistence of bone marrow micrometastases in patients receiving adjuvant therapy for breast cancer: results at 4 yearsInt J Cancer 114:94–100CrossRefGoogle Scholar
  31. 31.
    Pantel K, Schlimok G, Braun S, Kutter D, Lindemann F, Schaller G, Funke I, Izbicki JR, Riethmuller G. (1993) Differential expression of proliferation-associated molecules in individual micrometastatic carcinoma cellsJ Natl Cancer Inst 85:1419–1424CrossRefPubMedGoogle Scholar
  32. 32.
    Slamon JD, Leyland-Jones B, Shak S, et al (1998) Addition of HerceptinTM (humanized anti-HER2 antibody) to first-line chemotherapy for HER2 overexpressing metastatic breast cancer markedly increases anti-cancer activity: a randomized, multinational controlled phase III trialProc Natl Acad Sci USA 17:98 (abstr 377)Google Scholar
  33. 33.
    Solomayer E-F, Diel IJ, Wallwiener D, Bode S, Meyberg G, Sillem M, Gollan C, Kramer MD, Krainick U, Bastert G. (1997) Prognostic relevance of urokinase plasminogen activator in micrometastatic cells in the bone marrow of patients with primary breast cancerBr J Cancer 76: 812–818PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, Inc. 2005

Authors and Affiliations

  • Sven Becker
    • 1
  • Graziella Becker-Pergola
    • 1
  • Diethelm Wallwiener
    • 1
  • Erich-Franz Solomayer
    • 1
  • Tanja Fehm
    • 1
  1. 1.Department of Gynecology and ObstetricsUniversity Hospital TübingenTübingenGermany

Personalised recommendations